Results 41 to 50 of about 16,284 (167)
In Silico Design of Novel Anticoagulant Peptides targeting Blood Coagulation Factor VIIa
Sultan Qaboos University Medical Journal, 2011 Objectives: The coagulation cascade initiated during vascular injury prevents bleeding. Unwanted clot formation is however detrimental and requires the use of anticoagulants for prophylaxis and treatment.
Manal S Q Al-Amri +3 more
doaj
Stroke intensive care: voice a view
Анналы клинической и экспериментальной неврологии, 2007 Modern methods of acute stroke treatment are analyzed: traditional and mechanical thrombolysis, intraventricular thrombolysis, recombinant activated factor VIIa for acute intracerebral hemorrhage, hemicraniectomy.
M. A. Piradov
doaj +1 more source
People and Nature, EarlyView.Abstract Volunteers have been involved in nature observations for decades through citizen science initiatives, providing large data sets as well as problem identification that allow a more complete understanding of many natural phenomena. Although communication is a core component in citizen science, the key factors that determine its effectiveness in ...
Kristiina Gibson +18 more
wiley +1 more source
Mediterranean Journal of Hematology and Infectious Diseases, 2014 Diffuse alveolar hemorrhage is a serious complication post stem cell transplantation with no proven definitive treatment, resulting in high mortality. Recombinant factor VIIa has been occassionaly used in such patients with good results. We report here a
Dharma Choudhary +3 more
doaj
Hematology Reports, 2018 A 52 year-old male presented with neck pain after undergoing thyroidectomy for a goiter three weeks prior which was complicated by a neck hematoma requiring evacuation.
Anthony L. Nguyen +3 more
doaj +1 more source
Frontiers in Neurology, 2021 To date, many studies using the controlled cortical impact (CCI) mouse model of traumatic brain injury (TBI) have presented results without presenting the pathophysiology of the injury-core itself or the temporal features of hemorrhage (Hrr).
Hyejin Joo +5 more
doaj +1 more source
BRD9 inhibition as potential treatment option for testicular germ cell tumors
Andrology, EarlyView.Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen +5 more
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini +4 more
wiley +1 more source
HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa
Zdravniški Vestnik, 2004 Background. Recombinant factor VIIa can induce hemostasis and controls bleeding in surgery in hemophilia inhibitor patients and in other hemostatic disorders, e.g.
Dušan Andoljšek, Samo Zver
doaj
Haemophilia, EarlyView.ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju +5 more
wiley +1 more source